Asker’s five-insider buy cluster tests the SEK 60-64 zone

A distributor that grows by buying, and why that matters now

Asker Healthcare Group AB (publ) (Asker Healthcare Group AB (publ)) makes its money the old-fashioned way for a modern roll-up, it buys medical equipment and supply businesses across Europe, then tries to wring scale, purchasing power and operating leverage out of a fragmented market. That model is why the stock does not trade like a sleepy distributor. It trades like a judgment on execution, integration and whether the next acquisition adds more than it costs.

The late-September insider cluster lands against that backdrop. The shares were sitting in the SEK 60 to 64 range, the company had just posted a solid second quarter, and the broader Swedish market was not exactly in distress. OMXS30 had been grinding higher through September, while Asker had spent the year lagging. That is the tension here. The business has been delivering growth. The stock has not been rewarding patience.

Five buyers, one name, and a stock that had already been marked down

The filing trail is straightforward. Peter Nilsson, who heads the North business area, bought 7,532 shares between September 24 and 25 at an average SEK 61.17, for about SEK 460,700. Board member Joachim Zetterlund bought 10,000 shares on September 25 at SEK 60.45. Board member Mikael Vinje bought 30,000 shares on September 24 at SEK 61.46. Mattias Jaran bought 33,000 shares on September 23 at about SEK 60.58. Susanne Nilsson added 2,700 shares on September 24 at SEK 61.50, and a later September 28 filing reported a smaller buy by Nilsson valued at about EUR 26,877 euro-normalised.

That is a lot of buying for a stock that had already been weak over the prior year. The sources cited put Asker down roughly 23% to 28% over twelve months, while the Swedish healthcare industry was up 2.5% and the broader market up 13% over the same stretch. So this was not a case of insiders chasing momentum. They were buying into a name that had already been punished relative to its peers and the index.

Our scoring puts the name at 4.9, and the reason is plain enough. InsiderTrades data flags a wide cluster, five insiders trading the same name in the same direction over the past quarter, plus a filing value that is tiny relative to the company’s market value. The euro-normalised filing value near EUR 26,877 is not the point by itself. The point is that the buying came from several seats around the table, not from one lonely director trying to make a statement.

Q2 showed the machine still turning

Asker’s second quarter, ended June 30, gives the insider buying its business context. Net sales rose 18% year over year to SEK 4,686 million, with 5% organic growth. Adjusted EBITA increased 24% to SEK 471 million, and the margin reached 10.0%, which the company said met its medium-term target. First-half revenue reached SEK 9,207 million, up 15%. Trailing twelve-month revenue stood at SEK 18.01 billion.

Those are not the numbers of a business that has lost its operating rhythm. They are the numbers of a serial acquirer that is still getting some lift from scale and acquisitions while keeping organic growth ahead of the market. That matters because the market does not usually give a distributor much credit for being merely busy. It pays for evidence that the bolt-ons are adding earnings, not just revenue. Asker’s Q2 did that, at least on the face of it.

The stock, though, had not caught up. It was trading around SEK 60 to 64 in late September, and one report put the close near SEK 63.65 on September 29. That leaves you with a familiar gap in this kind of name. The company can report decent growth and margin progress, while the share price still reflects skepticism about how long the acquisition engine can keep compounding without friction.

How the cluster reads against the data

InsiderTrades data gives the mid-cap buy bucket a 90-day win rate of 50% and an average 90-day return of 4.35%, with a 365-day average return of 84.89%. That is useful, but only in the way a weathered map is useful. It tells you how this kind of trade has behaved on average. It does not tell you what Asker will do next.

The cluster itself is the more interesting part. The dossier shows five distinct insiders, nine recent declarations, and a run of buys that includes Peter Nilsson on September 27, 28 and 29, then Joachim Zetterlund and Mikael Vinje on September 25, and Mattias Jaran on September 24. That is a pattern of repeated accumulation, not a one-off gesture. You do not need to overread it to see the message. The people filing these trades were willing to add exposure after the stock had already been weak and after the company had already delivered a decent quarter.

Still, the limits matter. A cluster can reflect confidence, but it can also reflect routine portfolio behavior, compensation timing, or a view that the stock is simply cheap relative to its own history. The filing does not tell you which of those is true. It only tells you that several insiders chose to buy at the same time, and that is enough to make the name worth a closer look.

Why Asker trades like a quality roll-up, not a plain distributor

Asker is not a one-line healthcare stock. It is a serial acquirer focused on Europe, and that changes how you should read both the business and the share price. A plain distributor lives and dies on volume, pricing and working capital discipline. A roll-up adds another layer. You have to watch integration, acquisition cadence, leverage and whether the acquired businesses actually improve the group’s earnings quality.

That is why the valuation debate around Asker has been so persistent. The sources cited compare it with Swedish healthcare names such as Medicover, Attendo and Ambea, and with international names like Abbott Laboratories and Medtronic. The point is not that these are perfect comps. They are not. The point is that Asker has often been treated as a premium compounder because it has delivered growth through acquisition and scale, while the market still keeps one eye on leverage and execution risk. The cited screens also put Asker on a trailing multiple around 30 to 34 times, above lower-multiple Swedish peers in the same broad universe.

That premium is easier to defend when growth is broad and margins are moving the right way. It gets harder when the stock has already de-rated and the market starts asking whether the next acquisition cycle will be as clean as the last one. The late-September buying says insiders were willing to lean the other way. They were buying into the gap between what the business had just reported and what the share price was still implying.

The market backdrop was not hostile, just indifferent

The broader tape was not giving Asker much help, but it was not punishing healthcare either. OMXS30 was near 3,280 to 3,317 points in late September and up roughly 15% year to date through September 28, with only modest weekly fluctuations. That matters because a weak stock inside a firm index can sometimes be dismissed as a market problem. Here, that excuse is thin. The index was fine. Asker was the one lagging.

The healthcare sector backdrop was mixed rather than dramatic. The cited material points to sector rotation themes, with some names in the space trading on growth expectations and others on lower multiples. Asker sits awkwardly between those poles. It has the growth profile of a compounder and the operational baggage of an acquirer. That makes it more sensitive to any hint that integration is slipping or that the market is tiring of the story.

No fresh analyst commentary appeared in the immediate cluster window, though earlier September notes included a downgrade by DNB Carnegie. That is relevant because it means the insider buying did not arrive alongside a fresh broker upgrade or a new narrative from the sell side. The insiders were buying into a stock that had already been argued over, not into a new consensus trade.

What to watch in the next quarter

The next test is whether Asker can keep the operating numbers moving while the market digests the buying. The Q2 report already showed 18% sales growth, 5% organic growth and a 10.0% adjusted EBITA margin. If the next update shows that the margin held and the acquisition engine kept adding without a stumble, the cluster will look more like informed accumulation than opportunistic nibbling.

If the next quarter disappoints, the same filings will look less impressive. That is the risk with insider buying in a serial acquirer. The trade can be well timed and still not matter much if the business hits a patch where integration costs, leverage or slower organic growth start to bite. Asker’s net debt to EBITDA was cited around 2.2x to 2.4x after acquisitions, which is not alarming for the sector, but it is not nothing either. A roll-up with leverage always has to keep earning its way forward.

InsiderTrades data also puts the strategy window at 90 days, with a point-in-time backtest headline of 0.99, 10.2% (STOXX Europe 600 on the same dates: 9.9%) and (figure withdrawn, see audit 231) on the restricted EU venue universe, subject to the usual caveats about regime and search-aware deflation. That is a screen, not a thesis. For Asker, the thesis still comes down to whether the company can keep turning acquisitions into margin and cash flow while the stock remains below the level insiders were willing to buy in late September.

The filing date is already behind you. The next company report is not.

Sources and filings behind the cluster

The insider trail was reported in Borsvärlden, Marketscreener, EFN, Placera and Finanstidning, with the company’s Q2 report published through Cision and market context from Nasdaq OMX and the stock screens cited above. The first thing to watch now is whether the next quarterly update confirms that the 10.0% adjusted EBITA margin was a floor, not a peak.

This is not investment advice.

Dig deeper: Peter Nilsson's filing track record.

This is not investment advice.